Travere Therapeutics recently reported that the FDA has extended its review of the supplemental New Drug Application for ...

The U.S. Food and Drug Administration has extended its review for the expanded ​use of Travere Therapeutics’ drug to treat a ...

A fresh setback on the regulatory front was the development that put a damper on Travere Therapeutics ( TVTX 14.63%) stock on ...

The U.S. Food and Drug Administration has extended its review for the expanded use of Travere Therapeutics’ drug to treat a ...

Travere Therapeutics FY25 sales surged on Filspari, but the FDA FSGS label decision was delayed to April. Click here to read ...

If you are wondering whether Travere Therapeutics at around US$29.11 is priced for opportunity or risk, the next sections ...

As of Tuesday, January 13, Travere Therapeutics, Inc.’s TVTX share price has dipped by 27.74%, which has investors ...

Much is riding on Travere Therapeutics’ bid to gain an expansion for Filspari to treat focal segmental glomerulosclerosis ...

U.S. FILSPARI reaches all-time highs of 908 new PSFs and net product sales of approximately $103 million in 4Q 2025Company ...

Lulu’s Fashion Lounge Holdings Inc (NASDAQ: LVLU) shares dipped 10.4% to $10.89 in pre-market trading. Lulu’s Fashion Lounge ...

Travere Therapeutics shares fall after the FDA extends its review timeline for Filspari's sNDA in FSGS, pushing the decision ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.